A single dose of psilocybin changed the wiring of mouse brains within hours, according to a study that tracked individual synapses rather than whole brain regions.
What the imaging showed
Researchers led by the University of California, Santa Cruz, reported in Nature Neuroscience that the compound sped up both the formation and the maturation of new neural connections. It also promoted the removal of some connections that already existed, a pruning step that normally takes much longer.
The team then looked at animals whose circuits had been disrupted by chronic stress. In those mice, psilocybin helped restore the affected circuits, which is the effect most often cited by researchers studying depression and trauma.
Two pathways, not one
The finding that drew most attention is a separation of effects. The cellular mechanisms that drive the structural rewiring appeared to work through different pathways from the ones that produce hallucinogenic behaviour. The mice showed a behavioural response that the authors interpret as evidence the plasticity can occur without the psychedelic experience.
If that holds in people, it opens a route to treatment that avoids the hours of altered perception that make psychedelic therapy expensive to deliver. A patient would still need clinical supervision, but perhaps not a dedicated room, a therapist for the full session and a day of recovery.
Why mice are not people
Rodent results have misled the field before. Mouse prefrontal circuits differ from human ones, doses are not directly comparable, and the study measured structure over hours and days, not mood over months. The strongest human evidence for psilocybin still comes from small trials in depression and addiction, with mixed results and modest sample sizes.
The work does add a mechanism to a field that has mostly relied on outcomes. It suggests the drug acts less like a switch that turns plasticity on and more like a temporary loosening of the rules that decide which connections survive.
The authors say the next step is to find compounds that keep the rewiring and drop the hallucination, a target several companies are already chasing with non-psychedelic analogues.